🚀 VC round data is live in beta, check it out!
Elanco Valuation Multiples
Discover revenue and EBITDA valuation multiples for Elanco and similar public comparables like Regencell Bioscience, BridgeBio Pharma, Ionis Pharmaceuticals, Neurocrine Biosciences and more.
Elanco Overview
About Elanco
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Founded
2018
HQ
Employees
9.4K
Website
Sectors
Financials (LTM)
EV
$16B
Elanco Financials
Elanco reported last 12-month revenue of $5B and EBITDA of $917M.
In the same LTM period, Elanco generated $3B in gross profit, $917M in EBITDA, and $483M in net income.
Revenue (LTM)
Elanco P&L
In the most recent fiscal year, Elanco reported revenue of $5B and EBITDA of $901M.
Elanco expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $917M | XXX | $901M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $483M | XXX | $473M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Elanco Stock Performance
Elanco has current market cap of $13B, and enterprise value of $16B.
Market Cap Evolution
Elanco's stock price is $26.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16B | $13B | 0.0% | XXX | XXX | XXX | $0.95 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialElanco Valuation Multiples
Elanco trades at 3.5x EV/Revenue multiple, and 18.0x EV/EBITDA.
EV / Revenue (LTM)
Elanco Financial Valuation Multiples
As of March 19, 2026, Elanco has market cap of $13B and EV of $16B.
Equity research analysts estimate Elanco's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Elanco has a P/E ratio of 26.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV (current) | $16B | XXX | $16B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 18.0x | XXX | 18.3x | XXX | XXX | XXX |
| EV/EBIT | 20.9x | XXX | 21.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.3x | XXX | 6.4x | XXX | XXX | XXX |
| P/E | 26.8x | XXX | 27.4x | XXX | XXX | XXX |
| EV/FCF | 40.2x | XXX | 43.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Elanco Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Elanco Margins & Growth Rates
Elanco's revenue in the last 12 month grew by 6%.
Elanco's revenue per employee in the last FY averaged $0.5M.
Elanco's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Elanco's rule of X is 34% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Elanco Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 20% | XXX | — | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Elanco Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Regencell Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| BridgeBio Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ionis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurocrine Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Sino Biopharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elanco M&A Activity
Elanco acquired XXX companies to date.
Last acquisition by Elanco was on XXXXXXXX, XXXXX. Elanco acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Elanco
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialElanco Investment Activity
Elanco invested in XXX companies to date.
Elanco made its latest investment on XXXXXXXX, XXXXX. Elanco invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Elanco
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Elanco
| When was Elanco founded? | Elanco was founded in 2018. |
| Where is Elanco headquartered? | Elanco is headquartered in United States. |
| How many employees does Elanco have? | As of today, Elanco has over 9K employees. |
| Who is the CEO of Elanco? | Elanco's CEO is Jeffrey N. Simmons. |
| Is Elanco publicly listed? | Yes, Elanco is a public company listed on NYSE. |
| What is the stock symbol of Elanco? | Elanco trades under ELAN ticker. |
| When did Elanco go public? | Elanco went public in 2018. |
| Who are competitors of Elanco? | Elanco main competitors are Regencell Bioscience, BridgeBio Pharma, Ionis Pharmaceuticals, Neurocrine Biosciences. |
| What is the current market cap of Elanco? | Elanco's current market cap is $13B. |
| What is the current revenue of Elanco? | Elanco's last 12 months revenue is $5B. |
| What is the current revenue growth of Elanco? | Elanco revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Elanco? | Current revenue multiple of Elanco is 3.5x. |
| Is Elanco profitable? | Yes, Elanco is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Elanco? | Elanco's last 12 months EBITDA is $917M. |
| What is Elanco's EBITDA margin? | Elanco's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Elanco? | Current EBITDA multiple of Elanco is 18.0x. |
| What is the current FCF of Elanco? | Elanco's last 12 months FCF is $410M. |
| What is Elanco's FCF margin? | Elanco's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Elanco? | Current FCF multiple of Elanco is 40.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.